<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688230</url>
  </required_header>
  <id_info>
    <org_study_id>AP218797</org_study_id>
    <secondary_id>2018-003439-31</secondary_id>
    <secondary_id>AIO-KRK-0318/ass</secondary_id>
    <nct_id>NCT03688230</nct_id>
  </id_info>
  <brief_title>Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.</brief_title>
  <acronym>AMELION</acronym>
  <official_title>AMELION: A Randomized, Double Blinded, Phase 2, Efficacy and Safety Study of Abituzumab (EMD 525797) in Combination With Cetuximab and FOLFIRI Versus Placebo in Combination With Cetuximab and FOLFIRI in First-line RAS Wild-type, Left-sided, Metastatic Colorectal Cancer Patients With High ανβ6 Integrin Expression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SFJ Pharmaceuticals X, LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SFJ Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academic and Community Cancer Research United</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SFJ Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the experimental drug
      abituzumab (EMD525797) in combination with cetuximab and FOLFIRI in RAS wild-type,
      left-sided, metastatic colorectal cancer patients with high ανβ6 integrin expression.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Co-development decision
  </why_stopped>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>16 months</time_frame>
    <description>Progression free survival per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>68 months</time_frame>
    <description>The overall survival is defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>16 months</time_frame>
    <description>ORR will be estimated as the proportion of responders in each treatment arm, defined as a patient whose best overall response is PR or better during the treatment period according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of Response (DPR)</measure>
    <time_frame>16 months</time_frame>
    <description>Depth of response will be estimated as the maximum percent tumor shrinkage during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Tumor Shrinkage (ETS)</measure>
    <time_frame>68 months</time_frame>
    <description>ETS will be estimated as the proportion of patients achieving a ≥20 % decrease from baseline in the sum of longest tumor diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Resection Rate With a Potentially Curative Intent</measure>
    <time_frame>16 months</time_frame>
    <description>Patients for whom the resectability of metastases becomes evident during the study therapy should undergo a surgical resection of the metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events summarized by CTCAE severity grade (v5.0).</measure>
    <time_frame>68 months</time_frame>
    <description>Adverse events will be summarized by body system, preferred term, severity, and relationship to treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Abituzumab + Cetuximab + FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab:
400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
(60 min [± 5 min] after completion of the cetuximab infusion) Abituzumab 1000 mg: every 2 weeks for 60 min
(60 min [± 5 min] after completion of the abituzumab infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Cetuximab + FOLFIRI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cetuximab:
400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
(60 min [± 5 min] after completion of the cetuximab infusion) Placebo: every 2 weeks for 60 min
(60 min [± 5 min] after completion of the placebo infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abituzumab</intervention_name>
    <description>1000 mg IV</description>
    <arm_group_label>Abituzumab + Cetuximab + FOLFIRI</arm_group_label>
    <other_name>EMD525797</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo + Cetuximab + FOLFIRI</intervention_name>
    <description>400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min</description>
    <arm_group_label>Placebo + Cetuximab + FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated written informed consent prior to any study specific procedure;

          2. Age: ≥18 years;

          3. Evidence of newly diagnosed stage IV metastatic colorectal cancer. Primary tumor
             location on the left side of the Colon (including left splenic flexure) or rectum;

          4. Demonstrated wild-type RAS mutation status in the tumor (primary tumor or metastasis)
             by local assessment;

          5. Tumor tissue specimen shows high ανβ6 integrin expression, as determined by central
             laboratory assessment;

          6. Tumor tissue specimen (formalin-fixed, paraffin-embedded block) preferably from
             primary resection and/or if available from a surgical sample from metastatic site must
             be available for central laboratory based ανβ6 integrin expression analysis. (No Fine
             Needle Aspiration [FNA] will be accepted);

          7. At least 1 radiographically documented measurable lesion in a previously
             non-irradiated area according to RECIST (Version 1.1), i.e., this lesion must be
             adequately measurable in at least 1 dimension (longest diameter to be recorded) as ≥2
             cm by conventional techniques or ≥1 cm by spiral CT scan;

          8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1;

          9. Females of childbearing potential must have a negative pregnancy test at screening and
             be willing to have additional pregnancy tests during the study;

        Exclusion Criteria:

          1. Demonstrated any RAS or BRAF mutation;

          2. Prior anti-EGFR or other targeted therapy;

          3. Prior chemotherapy of the colorectal cancer, except for (neo) adjuvant therapy
             completed at least 6 months before randomization;

          4. Radiotherapy (localized radiotherapy for pain relief is allowed to non-target
             lesions);

          5. Investigational drug treatment for the treatment of malignancies in the past;

          6. Concurrent participation in another interventional clinical study;

          7. Pregnancy (exclusion confirmed with beta-hCG test) or lactation;

          8. Any history or evidence of brain metastases or leptomeningeal metastases;

          9. History of secondary malignancy within the past 5 years, except for basal cell
             carcinoma or carcinoma in situ of the cervix uteri, if treated with curative intent;

         10. Concomitant chronic systemic immune or hormone therapy not indicated in this study
             protocol (except for physiologic replacement; steroids up to 10 mg per day of
             prednisone equivalent or topical and inhaled steroids are allowed);

         11. Clinically relevant coronary artery disease (New York Heart Association [NYHA]
             functional angina classification III/IV), congestive heart failure (NYHA III/IV), or
             clinically relevant cardiomyopathy;

         12. Uncontrolled hypertension defined as systolic blood pressure &gt;160 mmHg and/or
             diastolic blood pressure &gt;100 mmHg under resting conditions;

         13. History of myocardial infarction in the last 12 months, or a high risk of uncontrolled
             arrhythmia, coagulation disorder associated with bleeding or recurrent thrombotic
             events, with the exception of arterial fibrillation treated with anti-coagulants;

         14. Recent peptic ulcer disease (endoscopically proven) within 6 months of randomization,
             chronic inflammatory bowel disease, or acute/chronic ileus;

         15. Active infection (requiring IV antibiotics and/or antiviral therapy), including active
             tuberculosis, active or chronic Hepatitis B or C, or ongoing HIV infection, AIDS;

         16. Presence of any contra-indications or known hypersensitivity to treatment with
             abituzumab, cetuximab, and FOLFIRI, or to any of the excipients of these drugs;

         17. Concomitant treatment with prohibited medications;

         18. Medical or psychological conditions that would not permit the patient to complete the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Arnold, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Tumorzentrum Hamburg</affiliation>
  </overall_official>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

